Oligonucleotide / ASO CDMOs with Clean FDA Inspection History

· updated as new inspection, certificate, and trial data enters the platform
9
CDMOs tracked
9
Fully scored
8
With FDA records
26
FDA inspections
40
EMA/MHRA GMP certs

Oligonucleotide CDMOs make antisense oligonucleotides (ASOs), siRNAs, and related nucleic-acid drugs by solid-phase synthesis, with downstream purification and conjugation (e.g. GalNAc). The segment has grown sharply alongside approved ASO and siRNA therapeutics.

Choosing an oligonucleotide CDMO turns on synthesis scale, chemistry breadth (phosphorothioate backbones, 2'-modifications, conjugation), purity, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 8 NAI (no action), 18 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Italy (16), United States (16), Spain (10), Germany (9), Belgium (5).

Last updated 2026-10-15. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
AJ
San Diego, CA · Osaka, JP
83.5 100.0 0 insp · 1 GMP None on file — —
2
CD
Plankstadt, DE · Caponago, IT · Boulder, CO
83.1 99.3 5 insp · 17 GMP 2025-11-14 · NAI — —
3
KE
Seraing, BE
81.6 99.9 1 insp · 4 GMP 2024-02-26 · VAI — —
4
ND
Milford, MA
80.3 100.0 4 insp · 0 GMP 2026-08-12 · NAI — —
5
BA
Bubendorf, CH
Hiring · 34 open roles
79.5 94.3 5 insp · 0 GMP 2026-05-20 · VAI — —
6
CRA
Albany, NY · Albuquerque, NM
Hiring · 48 open roles
79.5 100.0 2 insp · 18 GMP 2025-12-02 · NAI — —
7
PP
Torrance, CA · Strasbourg, FR · Malmo, SE
Hiring · 33 open roles
77.4 98.4 3 insp · 0 GMP 2025-05-15 · VAI — —
8
AX
Kulmbach, Germany
Fully evidenced
71.8 96.8 4 insp · 0 GMP 2025-01-16 · VAI — 3 programs
How we score CDMOs →

What to evaluate in a Oligonucleotide / ASO CDMO

Synthesis scale
Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile.
Chemistry & conjugation
Confirm experience with your backbone and modifications (phosphorothioate, 2'-MOE/F) and any conjugation (GalNAc, lipid) your molecule requires.
Purity & analytics
Full-length product, deletion/addition impurities, and residual metals drive release. Look for established orthogonal analytics.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Oligonucleotide / ASO CDMOs — Frequently Asked Questions

How many Oligonucleotide / ASO CDMOs have FDA inspection records?
CDMO Signal tracks 8 Oligonucleotide / ASO CDMOs with FDA inspection records and 40 EMA/MHRA GMP certificates across the group.
What should I look for in an oligonucleotide CDMO?
Match synthesis scale to your demand, confirm experience with your backbone chemistry and any conjugation (e.g. GalNAc), prioritize strong purity analytics, and a clean FDA and EMA/MHRA record.
What therapeutics do oligonucleotide CDMOs make?
Antisense oligonucleotides (ASOs), siRNAs, aptamers, and related nucleic-acid drugs — increasingly with conjugation chemistries like GalNAc for targeted delivery.
Related modalities
Plasmid DNA CDMOs mRNA / LNP CDMOs Biologics / mAb CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector